Top 20 of Hyperuricemia

Article title # Publications/# Citations

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

2004: Swedish Obese Subjects Study Scientific Group; CBouchard; BCarlsson; SDahlgren; BLarsson; AKLindroos; KNarbro; MPeltonen; ... CDSjöström; LSjöström; MSullivan; JTorgerson; HWedel;


Uric acid and cardiovascular risk.

2008: DIFeig; RJJohnson; DHKang;


Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.

2008: BCAstor; EJBenjamin; EBoerwinkle; JCoresh; ADehghan; CSFox; AHofman; SJHwang; ... WLKao; AKöttgen; DLevy; FRivadeneira; CMvan Duijn; JCWitteman; QYang;


Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.

2007: SBenner; DIFeig; MSGersch; RJJohnson; DHKang; TNakagawa; LGSánchez-Lozada; YSautin; MSSegal;


Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

2003: DFeig; JHerrera-Acosta; RJJohnson; JKanellis; DHKang; SKivlighn; MMazzali; BRodriguez-Iturbe; KRTuttle; SWatanabe;


Hyperuricemia induces endothelial dysfunction.

2005: ERBlock; JLFinch; RJJohnson; UMKhosla; KKrotova; WMu; TNakagawa; SPrabhakar; CRoncal; SZharikov;


Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.

2008: DIFeig; RJJohnson; BSoletsky;


Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

2005: MABecker; DEustace; NJoseph-Ridge; PAMacDonald; WAPalo; HRSchumacher; JStreit; RLWortmann;


Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.

2006: THKwan; KTLeung; YPSiu; MKTong;


A role for uric acid in the progression of renal disease.

2002: LFeng; LHan; RHarris; RJJohnson; DHKang; MMazzali; TNakagawa; LTruong; SWatanabe;


EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

2006: EULAR Standing Committee for International Clinical Studies Including Therapeutics; TBardin; VBarskova; PConaghan; MDoherty; JGerster; JJacobs; BLeeb; ... FLioté; GMcCarthy; PNetter; GNuki; EPascual; FPerez-Ruiz; APignone; JPimentao; LPunzi; ERoddy; TUhlig; WZhang; IZimmermann-Gorska;


Pathogenesis of gout.

2005: American College of Physicians; American Physiological Society; HKChoi; DBMount; AMReginato;


Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008.

2011: HKChoi; BJPandya; YZhu;


Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.

2009: EBoerwinkle; JCoresh; WBGuggino; AKöttgen; MKöttgen; OMWoodward;


Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress.

2007: RJJohnson; TNakagawa; YYSautin; SZharikov;


High serum uric acid as a novel risk factor for type 2 diabetes.

2007: ADehghan; AHofman; EJSijbrands; Mvan Hoek; JCWitteman;


Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

2010: JAmpuero; DArroyo; SGde Vinuesa; MGoicoechea; JLuño; ARincón; CRuiz-Caro; ÚVerdalles;


Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy.

2002: MMBarmada; AJBleyer; MCGorry; PSHart; TCHart; JSandhu; ZShihabi; BShirts; ... ASWoodard; LXu; HZhu;


Prevalence of the metabolic syndrome in individuals with hyperuricemia.

2007: HKChoi; ESFord;


Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.

2004: YIkemiya; TInoue; CIseki; KIseki; KKinjo; STakishita;